Alector Inc ALEC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALEC is a good fit for your portfolio.
News
-
Alector to Participate in Upcoming Healthcare Conferences
-
Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
-
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
-
Alector, GSK Get FDA Breakthrough Designation for Latozinemab
-
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
Trading Information
- Previous Close Price
- $5.25
- Day Range
- $4.80–5.20
- 52-Week Range
- $3.66–9.07
- Bid/Ask
- $4.75 / $6.35
- Market Cap
- $460.55 Mil
- Volume/Avg
- 505,642 / 660,560
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.53
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 244
- Website
- https://www.alector.com
Comparables
Valuation
|
Metric
|
ALEC
|
ACLX
|
KOD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.32 | 5.69 | 0.67 |
Price/Sales | 4.53 | 23.01 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ALEC
ACLX
KOD
Financial Strength
|
Metric
|
ALEC
|
ACLX
|
KOD
|
|---|---|---|---|
Quick Ratio | 3.08 | 5.94 | 6.84 |
Current Ratio | 3.18 | 6.06 | 6.93 |
Interest Coverage | — | −23.39 | −21,323.92 |
Quick Ratio
ALEC
ACLX
KOD
Profitability
|
Metric
|
ALEC
|
ACLX
|
KOD
|
|---|---|---|---|
Return on Assets (Normalized) | −13.64% | −6.26% | −29.40% |
Return on Equity (Normalized) | −54.21% | −12.08% | −49.54% |
Return on Invested Capital (Normalized) | −44.04% | −13.11% | −43.67% |
Return on Assets
ALEC
ACLX
KOD
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mstvzmbg | Ffmp | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zxbnpdsy | Ywknhj | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rxpvfkd | Ysgdfwm | $99.5 Bil | |
MRNA
| Moderna Inc | Rsvdwwxjj | Skdpc | $38.8 Bil | |
ARGX
| argenx SE ADR | Vhymvgmnh | Bylkw | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Lnsjttnsj | Xvby | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ljhwdbcdg | Hmsczbb | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nnrrrlx | Mvkfdjm | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vccmhntlqy | Wwmmdkb | $12.5 Bil | |
INCY
| Incyte Corp | Hjknjdx | Hnhrctb | $11.6 Bil |